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Anxiety Symptoms as a Predictor of Head and Neck Cancer Survival 
and Potential for Mediation by Cancer Treatment Response  
Introduction
Approximately 630,000 people are expected to develop head and neck cancer (HNC) this
year, ranking it the sixth most common cancer worldwide(Parkin, Bray, Ferlay, & Pisani, 2005).
White males are the most at-risk group for developing HNC--almost 3 times more likely than
white  females—and tobacco and alcohol  use greatly  increase that  risk(U.S. Cancer Statistics
Working Group, 2018). The impacts of HNC on patients include significant decreases in health-
related quality of life (HRQOL) paired with invasive surgeries that often result in severe facial
disfigurement. Tumors of the head and neck are rarely diagnosed in their early stages and are
often aggressive in nature, which emphasizes their high mortality.  Additionally, many do not
respond well to treatment, causing complications while costing patients valuable time. Therefore,
the typical patient newly diagnosed with HNC can expect his/her tumor(s) to already be at an
advanced stage, a decline in his/her ability to eat and/or communicate, expensive and invasive
multimodal treatment, and facial disfigurement after surgery, if performed. Each of these likely
circumstances contribute to patient feelings of anxiety about what brand of suffering awaits him/
her, which may influence the patient’s attendance to treatment and even the treatment’s outcome.
The  Diagnostic  and  Statistical  Manual  (DSM-5)  defines  generalized  anxiety  to  be
excessive  worry  that  is  difficult  to  control  and  causes  significant  impairment  in  social,
occupational, or other important areas of functioning(American Psychiatric Association, 2013).
Research has shown evidence of anxiety in HNC patients at all stages of the disease, but its
association  with  clinical  outcomes  remains  underrepresented  in  the  literature(Howren,
Christensen,  Karnell,  &  Funk,  2013).  For  example,  one  study  used  a  modified  distress
thermometer  to  assess  “mask  anxiety”  before  and  during  radiotherapy  (RT)  but  did  not
investigate  the  effect  of  that  anxiety  on  treatment  outcomes.  “Mask  anxiety”  does  well  to
illustrate the experience of many HNC patients. RT is the most common treatment for HNC and
demands the patient  lie  motionless  under an immobilizing mask for up to 15 minutes  while
radiation is applied to the target site. RT sessions are thus understandably a source of anxiety for
HNC patients, but it is only one of many worries for this patient population. A diagnosis of HNC
often includes anxiety for the receiving patient, which, depending on coping style, can decrease
treatment adherence(de Oliveira et al., 2017). Anxiety has also been shown to relate to difficulty
with remembering and recalling medical information, contributing to the likelihood of making
underinformed treatment decisions(Kessels, 2003). 
From a traditional physician’s perspective, treating a patient’s cancer may seem to be the
most  effective  way  to  alleviate  accompanying  anxiety.  However,  this  approach  neglects  to
consider  an anxious  cancer  patient’s  role  in  treatment,  specifically  how his/her  anxiety  may
affect adherence to treatment and treatment decisions (e.g. whether to begin chemotherapy). One
longitudinal study of 50 Non-Small-Cell Lung Cancer patients found that those who reported
heightened baseline anxiety were significantly more likely to experience treatment delay and/or
reduction(Greer,  Pirl,  Park,  Lynch,  &  Temel,  2008).  Rather,  coping  style,  (the  patterns  of
behavior one is likely to respond with when confronted with stress) may provide a more accurate
predictor  of  behavior  regarding  treatment.  An  avoidant  coping  style  is  characterized  by  a
diversion of attention from a stress-causing stimulus. In the case of a cancer patient, an avoidant
coping style could mean that he/she does not return to a healthcare facility for follow-up scans or
even for expensive treatments such as RT. As for making appropriate treatment decisions, the
presence  of  anxiety  brings  with  it  the  potential  to  misinterpret  the  severity  of  one’s  own
condition.  As more medical  information is presented to a patient,  more is forgotten,  and the
amount  forgotten  is  positively  correlated  with  anxiety  level(Ley,  1979).  This  could  include
details  about  the  disease’s  progression  or  treatment  recommendations.  For  example,  in  this
situation an anxious individual may conclude that he/she is not ill enough to justify beginning a
chemotherapy regimen, thus potentially making a decision against his/her best interest due in
part  to  anxiety’s  influence  on  his/her  memory  for  medical  information.  However,  anxiety’s
effects  are  not  limited  to  treatment  adherence  and  decisions.  There  are  also  biological
mechanisms that can be uniquely detrimental to cancer patients.
When an individual experiences significant symptoms of anxiety, he/she is subjected to
consistently  high  levels  of  nervousness  and  worry  that  together  create  the  psychological
experience of distress. There are numerous physiological consequences of chronic stress such as
immune system suppression(Segerstrom & Miller, 2004) and damaged hippocampal receptors
causing impaired memory(Wingenfeld & Wolf, 2014). Chronic stress has also been linked to the
upregulation  of  the  nuclear  factor  kappa  light-chain-enhancer  of  activated  B  cells  (NF-κB)
pathway,  which  mediates  the  synthesis  of  proinflammatory  molecules  throughout  the
body(Gupta et al., 2011). This is significant because when dysregulated, this pathway is heavily
implicated  in  the  expression  of  symptoms  of  cancer:  depression,  fatigue,  disordered  sleep,
anxiety,  cognitive impairment,  cachexia,  anorexia,  delirium, and neuropathic pain.  One study
found a clear relationship between anxiety and NF-κB activity in breast cancer patients(Antoni et
al.,  2012).  The  experiment  involved  treating  patients  with  a  cognitive-behavioral  stress
management  intervention  and measuring  the activity  of NF-κB at  baseline,  6,  and 12-month
follow-ups. It was concluded that the intervention had a significant effect on the NF-κB pathway,
decreasing its activity and therefore decreasing its threat to patient health. This study serves to
highlight two ideas important to this paper: how maladaptive thinking - such as that present in
anxiety - can influence a patient’s physical health via the NF-κB pathway, and how treating that
maladaptive  thinking has  the  potential  to  ameliorate  health  problems exacerbated  by NF-κB
activation
Upregulation  of  NF-κB may be  stimulated  by distress,  diet,  chemotherapy,  infection,
obesity, and addiction with the presence of more than one stimulus creating a cumulative effect
on  the  pathway(Gupta  et  al.,  2011).  That  is,  an  individual  who  is  distressed,  obese,  and/or
possesses an infection will have a more active NF-κB pathway than an individual who is only
obese (depending on the severity of each condition). Therefore, an individual facing multiple
upregulating stimuli has a greater chance of exhibiting the debilitating symptoms of cancer. In a
patient  already  diagnosed  with  cancer,  these  upregulating  stimuli  serve  to  exacerbate  their
condition.  Note  that  chemotherapy  itself  has  been  shown  to  dysregulate  NF-κB  signaling,
meaning that even treatment has the potential  to work against the patient to some degree. A
typical cancer patient faces more than one of the above stimuli simultaneously and experiences
more than one symptom of the disease(Cleeland,  2007).  In this  situation,  a predisposition to
anxiety may further magnify the effects of cancer on the body. Therefore, the presence of anxiety
in the cancer patient population is one of physiological concern because it influences the severity
of cancer symptoms.
Beyond contributing to symptoms, NF-κB has been linked to cancer progression with
some calling it the root cause of head and neck squamous cell carcinoma(Monisha et al., 2017).
Research has indicated the activation of NF-κB is a precursor to malignancy and metastasis in
HNC, resulting in poorer overall  survival13.  Further,  NF-κB is a transcription factor for anti-
apoptotic genes, meaning its persistent activation endorses the survival of cancer cells and allows
them to proliferate  in  the body(Vander  Broek,  Snow, Chen, & Van Waes,  2014).  As a key
regulator  of  cell  life  and  death(Colombo,  Zambrano,  &  Agresti,  2018),  these  findings  are
concurrent with the influence of NF-κB signaling on symptomology and represent NF-κB as not
only a factor that influences cancer symptoms, but also one that contributes to the disease itself.
Strong evidence  suggests  that  the  NF-κB pathway links  the  experiences  of  stress  and other
stimuli to the behavior of cancer, and that it represents an obstacle in the treatment of HNC.
While assessment of NF-κB is beyond the scope of the current study, we present these data to
support the notion that symptoms of anxiety may be biologically linked to the progression of
cancer.
As  a  cancer  patient  continues  along  the  treatment  trajectory,  improvement  in  his/her
condition is measured by means of tumor response to treatment, which is evaluated via change in
tumor  size.  A  tumor’s  size  is  determined  by  its  largest  dimension(Shanbhogue,  Karnad,  &
Prasad,  2010),  and its  response to  treatment  is  categorized  by the change in  that  dimension
before and after treatment. From there, response to treatment is assessed to be in one of four
categories:  complete  response  (CR)  if  a  tumor  appears  to  be  completely  eliminated,  partial
response (PR) if the tumor’s largest dimension decreases by more than 50%, stable disease (SD)
if the tumor’s largest dimension reduces by less than 50% or increases by less than 25%, or
disease progression (DP) if the tumor’s largest dimension increases by more than 25%. Imaging
technologies such as computerized tomography (CT) and positron emission tomography (PET)
are  used  to  determine  response  to  treatment  and  are  typically  employed  3-6  months  post-
treatment to avoid misinterpretations related to delayed effects of radiation on the body (e.g.,
inflammation)(Hermans,  2004).  Although  there  have  been  great  advances  in  RT  over  the
years(Gregoire, Langendijk, & Nuyts, 2015), most HNC patients are diagnosed at an advanced
stage (III or IV) and often face poor prognoses(Cognetti, Weber, & Lai, 2008). Even those who
respond well to treatment remain at risk, as up to 60% of patients diagnosed with HNC develop
recurrent  disease,  sometimes  years  after  completing  treatment.  Even  soon  after  completing
treatment, recurrences or treatment failures may occur.
Treatment failure is a useful predictor of overall survival in cancer research. For example,
a  study involving patients  with  non-small-cell  lung cancer  was  able  to  develop formulas  to
determine  the  effect  of  treatment  response  on  one-year  survival(Shanafelt,  Loprinzi,  Marks,
Novotny, & Sloan, 2004). An individual whose response to treatment is categorized as SD will
generally have shorter-term survival compared to an individual with an identical condition (type,
stage, and site) categorized as CR or PR, and the category CR does well to represent patients’
disease trajectory as optimistic.  While the relationship between optimal treatment response and
overall  survival  is  frequently used in early  evaluations  assessing the efficacy of new cancer
treatments, treatment failure commonly portends poorer overall survival. 
Anxiety’s role in overall survival is less clear mainly because it is understudied(Roth &
Massie,  2007).  Nevertheless,  biological  evidence  suggests  it  plays  a  role  in  the
development/escalation  of  cancer  symptoms,  therefore  having  a  negative  effect  on  survival.
Further, proinflammatory cytokines produced by the NF-κB pathway--which is upregulated by
factors including stress and anxiety--are implied to cause mood disruption that can worsen the
quality of life of a patient undergoing cancer treatment(Capuron, Ravaud, & Dantzer, 2000; Jehn
et al., 2006; Musselman et al., 2001). In this manner, anxiety has the potential to complicate the
treatment of HNC and increase mortality. 
In  contrast  to  the  effects  of  depression  on  cancer  symptomology  and  trajectory,  the
effects  of  anxiety  on  the  cancer  patient  population  beginning  treatment  remain
understudied(Howren et al., 2013). This includes the effect of anxiety on treatment response and
overall survival, which should be investigated due to the posited relationship between anxiety
and  NF-κB  activation,  especially  since  literature  on  the  relationship  between  anxiety  and
treatment response is scant. It is also plausible that treatment response may explain some of the
influence of anxiety level and on overall  survival,  meaning treatment response likely plays a
mediating role on anxiety and survival.  This study aims to address the variables  of anxiety,
treatment  response,  and  overall  survival  via  a  longitudinal  design  that  measures  anxiety
symptoms at the start of treatment, tumor response after completion of treatment 5 months later,
and two-year overall survival. We hypothesize that higher pretreatment anxiety levels in HNC
patients  will  predict  poorer  overall  two-year  survival.  We  also  hypothesize  that  higher
pretreatment anxiety levels will predict a higher likelihood of subsequent HNC treatment failure.
Finally, we expect that the relationship between higher pretreatment anxiety and poorer two-year
overall survival will be mediated by treatment failure.
Methods
Participants and Procedures
All new patients who presented to the multidisciplinary head and neck cancer clinic at the
James Graham Brown Cancer Center between October, 2013 and March 2017 were reviewed.
This  study received approval  from our institutional  review board with a  waiver of informed
consent and an approval number of 13.0053. Participants completed anxiety assessments prior to
or during presentation at the multidisciplinary treatment planning visit.  Patients had typically
received  notice  of  their  biopsy-proven  diagnosis  of  HNC  1-4  weeks  before  presentation.
Treatment  recommendations  generally  included  surgical  extirpation  of  disease,  radiation,
chemotherapy  or  some  combination  of  the  three.  Our  clinic  sees  approximately  200  HNC
patients  per  year,  including  patients  with  recurrent  or  metastatic  disease,  and  patients  with
disease at sites other than of the head and neck (e.g., thyroid, skin melanoma). Approximately
400-500 new primary HNC patients were referred to our clinic during the 4.5-year study period.
Patients who returned completed data on anxiety symptoms (approximate N=450) are the focus
of the current analysis. 
Measures
Clinical Variables
Patient demographics of age, sex, and alcohol and smoking history were collected from
intake forms. Only patients with HNC as a primary disease were analyzed, excluding those with
recurrent  or  metastatic  disease.  Staging  followed  the  guidelines  of  the  American  Joint
Commission  on  Cancer  and  was  determined  at  the  time  of  presentation  using  all  available
clinical, pathologic, and radiographic data. Tumor location was classified into 1 of 4 categories:
oral,  oropharyngeal,  hypopharyngeal,  or  laryngeal.   Medical  records  were reviewed after  all
participants had completed treatment, and they provided data on tumor response to treatment and
overall  two-year  survival.  Patients  were  coded as  poorly  responsive  if  their  records  showed
clinical  evidence  of  disease  persistence  or  tumor  progression.  Response  to  treatment  was
assessed to be in one of four categories:  complete  response (CR) if a tumor appeared to be
completely eliminated, partial response (PR) if the tumor’s largest dimension decreased by more
than 50%, stable disease (SD) if the tumor’s largest dimension reduced by less than 50% or
increased  by  less  than  25%,  or  disease  progression  (DP)  if  the  tumor’s  largest  dimension
increased by more than 25%. Overall two-year survival was calculated from the date patients
entered  the  study,  which  was  also  the  date  that  patients  met  with  physicians  to  plan  their
treatment regimen.
Anxiety 
Anxiety symptoms were measured at the time of entry using the Generalized Anxiety
Disorders  –  7  item scale  (GAD–7),  which  has  demonstrated  adequate  reliability  as  well  as
construct,  criterion,  and  procedural  validity(Spitzer,  Kroenke,  Williams,  &  Löwe,  2006).  It
instructs respondents to indicate on a scale of 0-3 how frequently they have been bothered by 7
different anxiety-related problems (e.g. “worrying too much about different things”) over the
past 2 weeks, with 0 representing “not at all” and 3 representing “nearly every day.”  Scores
range from 0-21 and encompass 3 categories of symptom severity. Scores from 5-9 indicate mild
severity, scores from 10-14 indicate moderate severity, and scores above 14 indicate the presence
of  severe  anxiety  symptoms.  A  score  of  10  is  generally  accepted  as  a  clinical  cutoff  for
significant symptomology that may require treatment. The GAD-7 has been tested as a screening
tool  for Generalized  Anxiety Disorder in cancer  patients  and has been concluded to possess
adequate diagnostic accuracy among this population(Esser et al., 2018). Further, it has previously
been used to study HNC patients, where it was found to have adequate sensitivity and specificity
in determining the presence and severity of distress in its respondents(Polidoro Lima & Osório,
2014).
Statistical Analysis Plan. 
Descriptive and summary statistics 
Descriptive and summary statistics will be used to characterize clinical and demographic
features of the patient sample. Before analyses, independent variables will be centered at the
mean, and we will confirm all statistical assumptions are met when running tests of hypotheses. 
Hypothesis Tests
The  relationship  between  pretreatment  anxiety  and  two-year  overall  survival  will  be
examined with a Cox proportional hazards model. The relationship between pretreatment anxiety
and treatment failure will be tested with a logistic regression model. Tests of mediation on the
relationship  between  pretreatment  anxiety  and  overall  survival  will  then  be  performed  in
accordance with the MacArthur approach, in which centered predictors and their interaction term
are included(Kraemer, Kiernan, Essex, & Kupfer, 2008).  To show that B mediates A on C, it
must be shown that A, B, and C happen in that order, that A and B are correlated, and that B
explains all (complete) or part (partial) of the association between A and C. In a linear model,
that means that the main effect of B, the interaction between A and B, or both are statistically
significant. Cox models will be constructed to include pretreatment anxiety symptoms, treatment
failure, and the interaction between the two. 
In  order  to  check  for  possible  proxy  relationships  that  may  impact  our  tests  of
hypotheses,  Spearman  rank  correlations  will  assess  clinical  and  demographic  indicators,
including cancer stage, site of disease, age at diagnosis, sex, and tobacco history in pack-years.
Those that correlate with both anxiety and survival will be considered possible proxies according
to  the  MacArthur  definition(Kraemer  et  al.,  2008).  When  this  occurs,  Cox  models  will  be
constructed to include pretreatment anxiety symptoms, the possible proxy, and the interaction
between the two. All statistical tests will be 2-sided with  set at .05 (SPSS 25; IBM, Armonk,
New York). 
Power Analysis
A power analysis was completed based on a comparable study reporting depressive 
symptoms as a significant predictor of head and neck cancer survival among 134 patients 
experiencing 18 deaths(Zimmaro et al., 2018). The results suggested that our sample of ~450 
patients would attain 100% power to detect significant effects in hypothesized relationships.
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